MANA Therapeutics, a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the final closing of its Series A financing, bringing the total raised to $42 million. In addition, MANA closed a $7.5 million venture debt facility with Silicon Valley Bank with an initial tranche of $5 million available immediately.

MANA Therapeutics is harnessing the natural immune system to develop broadly accessible, ready-to-use cellular therapies to improve outcomes for cancer patients. By educating T-cells to target multiple tumor associated antigens without the need for genetic modification, MANA’s EDIFY™ platform provides the opportunity to deliver safe, effective, and repeatable therapies.
Our journey began with acute myeloid leukemia (AML) and we are advancing the science to develop additional proprietary and partnered programs for additional hematologic and solid tumors. https://www.manatherapeutics.com/

Mana Therapeutics Announces Final Closing Of Series A And Closing Of Venture Debt Facility

Description

Company Information

Mana Therapeutics Announces Final Closing Of Series A And Closing Of Venture Debt Facility

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information